Side-by-side · Research reference
GlutathionevsOvagen
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AHuman-MechanisticHUMAN-REVIEWED6/39 cited
BTheoreticalHUMAN-REVIEWED2/42 cited
Glutathione
Endogenous Tripeptide · Antioxidant
IV · Oral · Inhaled
Ovagen
Khavinson Bioregulator · Ovarian
OvarianTarget tissue
Di/Tri-peptidePeptide length
AnimalEvidence tier
Oral / SQ · Protocol varies
01Mechanism of Action
Parameter
Glutathione
Ovagen
Primary target
Intracellular redox systems, glutathione peroxidase, glutathione transferase
Ovarian tissue chromatin complexes
Pathway
Synthesized via glutamate-cysteine ligase (GCL) → γ-glutamylcysteine → glutathione synthetase (GS) → GSH
Tissue-specific peptide → Nuclear chromatin binding → Gene expression modulation → Cellular differentiation
Downstream effect
Reduction of reactive oxygen species, conjugation of electrophiles, maintenance of cellular thiol-disulfide balance, GPX4 activation for lipid peroxide reduction
Proposed ovarian functional support, fertility regulation, hormonal homeostasis restoration
Feedback intact?
—
Presumed physiological — Khavinson peptides described as regulatory, not replacement
Origin
Endogenous tripeptide; predominantly synthesized in liver, exported to extracellular space and tissuesTerrell 2025Hecht 2026
Extracted from bovine/porcine ovarian tissue; short synthetic peptides (2–4 amino acids)
Antibody development
—
—
02Dosage Protocols
Parameter
Glutathione
Ovagen
Endogenous synthesis
Hepatic synthesis ~10 g/day (basal rate)
Tissue-specific; demand-driven upregulation via Nrf2 signaling.
—
Exogenous oral
250–1000 mg/day
Bioavailability limited; gastric hydrolysis reduces systemic uptake.
—
IV supplementation
600–1200 mg (research protocols)
Used in clinical oxidative stress and hepatic detoxification studies.
—
Precursor strategy
N-acetylcysteine (NAC) 600–1200 mg/day
Provides cysteine for endogenous GSH synthesis; bypasses GI degradation.
—
Evidence basis
Animal mechanistic + human mechanistic
Theoretical / Russian-tradition
Standard dose
—
10–20 mg / day (oral) or 1–2 mg SQ
Extrapolated from Khavinson-school protocols; no ovagen-specific PubMed dose studies.
Frequency
—
Once daily or cyclical (10–20 days per month)
Cyclical protocols common in Khavinson bioregulator tradition.
Duration
—
4–12 weeks per cycle
Khavinson protocols typically 1–3 months; repeat cycles as needed.
Route
—
Oral (capsule) or subcutaneous
Oral absorption assumed for short peptides; SQ route mirrors other Khavinson bioregulators.
04Side Effects & Safety
Parameter
Glutathione
Ovagen
Oral supplementation
GI discomfort, bloating (mild, dose-dependent)
—
IV administration
Rare hypersensitivity, infusion site reaction
—
Inhalation
Bronchospasm risk in asthma (rare)
—
Tumor metabolism
Extracellular GSH catabolism supplies cysteine to tumors; theoretical concern in active malignancyHecht 2026
—
Reported adverse events
—
None documented in indexed literature
Theoretical hormonal effects
—
Ovarian stimulation — monitor for estrogen-sensitive conditions
Injection site reaction
—
Possible mild erythema (SQ route)
Long-term safety
—
Unknown — no PubMed-indexed RCTs
Absolute Contraindications
Glutathione
—Ovagen
- ·Active hormone-sensitive malignancy (breast, ovarian, endometrial)
- ·Pregnancy
Relative Contraindications
Glutathione
- ·Active malignancy (theoretical cysteine supply risk)Hecht 2026
- ·Severe asthma (inhaled formulations)
Ovagen
- ·History of estrogen-sensitive tumors (monitor)
- ·Polycystic ovary syndrome (PCOS) — theoretical ovarian hyperstimulation risk
- ·Endometriosis or fibroids (estrogen-responsive conditions)
05Administration Protocol
Parameter
Glutathione
Ovagen
1. Oral administration
Capsule or liquid form, 250–1000 mg once daily. Take on empty stomach for improved absorption, though GI hydrolysis limits bioavailability. NAC precursor strategy often preferred.
Typical dose: 10–20 mg once daily. Capsule form — taken on empty stomach, 20–30 min before meals. Khavinson tradition suggests morning administration.
2. Intravenous
Clinical protocols: 600–1200 mg slow infusion over 30–60 minutes. Used for acute oxidative stress, hepatic detoxification support. Administered in medical settings.
1–2 mg per injection. Reconstitute lyophilised powder with sterile water if required. Inject into abdomen or thigh; rotate sites.
3. Inhaled formulations
Nebulized GSH (research protocols). Monitor for bronchospasm in reactive airway patients. Used experimentally for pulmonary oxidative stress.
Common pattern: 10–20 days on, 10 days off. Aligns with menstrual cycle phases in some protocols. Repeat cycles for 2–3 months, then assess.
4. Precursor supplementation
N-acetylcysteine (NAC) 600–1200 mg/day PO. Provides cysteine substrate for endogenous GSH synthesis. Bypasses gastric degradation, preferred for chronic supplementation.
Lyophilised: room temperature, light-protected. Reconstituted: refrigerate 2–8 °C, use within 7–14 days.